Pfizer Wins Approval in New Indication for Blood Cancer Drug Adcetris

Pfizer secured an eighth indication for its blood cancer drug Adcetris after the FDA approved its use in adults, in combination with two other medications, to treat relapsed or refractory large B cell lymphoma. The approval was based on Phase 3 results that showed a statistically significant improvement in overall survival and progression-free survival compared to the two other medications, lenalidomide and rituximab, alone.